Skip to main content

Table 5 Clinical response after 1 year, by therapy

From: Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab

 

All therapies

ADA

MTX

TCZ

TOF

Patients (n)

149

49

23

50

27

Pretreatment DAS28-ESR

5.35 (4.40–6.45)

5.33 (4.34–627)

4.23 (3.84–5.12)

5.43 (4.57–6.51)

6.34 (5.74–7.11)

DAS28-defined remission

Y

N

Y

N

Y

N

Y

N

Y

N

Patients (n)

82

67

26

23

15

8

30

20

11

16

Pretreatment DAS28-ESR

5.00 (4.09–6.13)a

5.85 (4.90–6.77)

5.30 (4.06–5.83)

5.67 (4.82–6.77)

4.11 (3.75–4.43)

4.78 (4.24–5.27)

4.80 (4.23–6.27)b

6.02 (5.30–7.44)

6.60 (5.60–7.11)

6.28 (5.78–7.09)

Response rate

55 %

53 %

65 %

60 %

41 %

Pretreatment 14-3-3η (ng/ml)

0.50 (0.16–4.95)

1.05 (0.19–7.75)

1.16 (0.20–9.06)

0.47 (0.13–2.14)

0.70 (0.17–1.89)

0.42 (0.16–14.55)

0.23 (0.09–3.03)b

4.02 (0.46–19.77)

1.05 (0.30–9.46)

1.56 (0.20–11.58)

1-yr 14-3-3η (ng/ml)

0.33 (0.10–1.45)

0.62 (0.14–3.11)

0.75 (0.14–2.96)

0.30 (0.13–1.17)

0.37 (0.11–0.62)

0.28 (0.07–18.33)

0.13 (0.08–0.75)b

1.52 (0.28–5.57)

1.24 (0.11–1.85)

1.27 (0.11–5.08)

Pretreatment CRP (mg/ml)

0.73 (0.15–3.12)

1.14 (0.26–3.40)

0.62 (0.14–5.01)

1.14 (0.40–5.32)

0.36 (0.06–0.83)

0.18 (0.08–1.34)

0.92 (0.14–2.18)

2.67 (0.40–3.50)

2.97 (0.56–5.22)

1.04 (0.33–2.98)

1-yr CRP (mg/ml)

0.03 (0.01–0.09)b

0.09 (0.02–0.37)

0.04 (0.02–0.13)a

0.14 (0.07–1.22)

0.05 (0.02–0.13)

0.12 (0.03–0.31)

0.01 (0.00–0.030)c

0.03 (0.01–0.18)

0.03 (0.02–0.16)

0.04 (0.03–0.28)

EULAR-defined good response

Y

N

Y

N

Y

N

Y

N

Y

N

Patients (n)

101

43

30

19

16

4

40

8

15

12

Pretreatment DAS28-ESR

5.32 (4.33–6.45)

5.77 (4.70–6.55)

5.33 (4.33–6.03)

5.32 (4.32–6.77)

4.21 (3.83–5.03)

4.42 (3.32–5.37)

5.02 (4.37–6.61)

5.75 (4.83–6.02)

6.60 (5.74–7.25)

6.10 (5.53–6.60)

Response rate

70 %

61 %

80 %

83 %

56 %

Pretreatment 14-3-3η (ng/ml)

0.62 (0.16–5.02)

1.48 (0.20–12.72)

0.61 (0.12–3.61)

0.70 (0.24–5.84)

0.65 (0.12–1.03)

1.05 (0.20–14.82)

0.37 (0.16–7.33)

10.34 (0.19– > 20)

1.05 (0.30–8.16)

1.56 (0.20–14.02)

1-yr 14-3-3η (ng/ml)

0.28 (0.10–1.51)b

0.80 (0.27–5.99)

0.45 (0.11–1.45)

0.36 (0.22–1.41)

0.30 (0.10–0.47)c

7.39 (0.53– > 18.33)

0.18 (0.08–2.02)b

3.42 (0.39– > 20)

1.24 (0.11–1.85)

1.35 (0.19–9.06)

Pretreatment CRP (mg/ml)

0.96 (0.21 – 3.35)

0.64 (0.23 –3.08)

0.80 (0.27 – 5.33)

0.68 (0.30 – 4.20)

0.16 (0.05–0.80)

0.33 (0.10–1.34)

1.10 (0.20–3.11)

0.60 (0.16–2.99)

2.18 (0.77–4.28)

1.04 (0.26–3.58)

1-yr CRP (mg/ml)

0.03 (0.01 – 0.12)c

0.11 (0.03 – 0.50)

0.05 (0.02 – 0.14)a

0.13 (0.07 – 1.50)

0.04 (0.02–0.24)

0.13 (0.03–0.22)

0.01 (0.00–0.05)a

0.06 (0.02–1.36)

0.03 (0.02–0.16)

0.07 (0.02–0.28)

  1. Abbreviations: ADA adalimumab, CRP C-reactive protein; DAS28-ESR Disease Activity Score in 28 joints with erythrocyte sedimentation rate, EULAR European League Against Rheumatism, MTX methotrexate, TCZ tocilizumab, TOF tofacitinib
  2. Values shown are median (interquartile range)
  3. a p < 0.001
  4. b p < 0.01
  5. c p < 0.05